December 1st, 2020
Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of diagnostic and therapeutic products in oncology and research services provider, announces today the opening of its new office in Boston at the Cambridge Innovation Center (CIC).
United States is one of the priority markets for the organization and the opening of a new office in the CIC, a local innovation ecosystem, will allow PROALT to better meet the future needs for the developments associated to its therapeutic products mainly. As a first step in the internalization strategy, the decision will offer a lot of strategical advantages for the future investments and outsourced activities.
Founded in 2006 and headquarters in Madrid, PROALT is a biotechnological company that has strengthened its position during last years as one of the local industry leaders in the development of first-in-class therapeutic monoclonal antibodies for the treatment of metastatic tumours. Its most advanced product PA-0661, a monoclonal antibody against cadherins_RGD for the treatment of metastatic colorectal cancer (mCRC), has showed promising results in animal models, delaying metastasis formation and achieving complete tumor eradication in most of the treated animals.